Interview with Francisco Piccolo, President, Biogen Idec Brazil
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Address: Av. Doutor Cardoso de Melo, 1.184, 17º andar Vila Olimpia São Paulo – SP – Brasil Cep: 04548-004,Brazil
Tel: +55 11 3568-3400
Web: http://www.biogenidec.com.br/
Biogen Idec Inc. (NASDAQ: BIIB) is a global biotechnology leader with products in oncology, neurology and immunology. Biogen Idec is committed to transforming scientific discoveries into advances and health care. The company’s include the discovery, research, development and biomanufacturing of medicine and a global commercial infrastructure.
Biogen Idec pursues the creativity of science with passion and discipline. For over 25 years, the company has grown through the discovery, development and commercialization of innovative products themselves and through strategic alliances.
Scientific excellence that achieves new standards of care drives the company’s work. Currently, more than twenty products are in clinical development to meet a number of important medical needs.
Biogen Idec has affiliates in Brazil, Canada, Australia, Japan and throughout Europe, including the international headquarters in Zug, Switzerland. The company currently employs approximately 3,600 people worldwide.
In Brazil, Biogen Idec is focused on the Multiple Sclerosis market, as an expert company in the disease, and is responsible for organizing World MS Day activities in the country.
Avonex, Tysabri
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could…
When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which…
In an exclusive interview, Otto Philipp Braun, part of medtech giant B. Braun’s family dynasty, discusses his achievements as MD in Brazil, the company’s operations in the country and globally, as…
When we met you in 2007, as the head of the former Igefarma, the company was undergoing a transition – from branded generics into dermocosmetics and women’s health. But since…
Rogerio, you were one of the people responsible for integrating two well-established companies in the Brazilian market with the acquisition of Exel by DHL in late 2005. How challenging was…
You have 25 years of experience in the Brazilian pharmaceutical industry, witnessing the major transformations of this market and the fast emergence of generics. Regarding your background and experience at…
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What was it about Brazil…
With its huge market of 186 million people; its current position as the largest pharma market in Latin America, with strong growth projected; the influx of foreign and local…
See our Cookie Privacy Policy Here
